Ascendis Pharma A/S (NASDAQ:ASND) Insider Flemming Steen Jensen Sells 19,460 Shares of Stock

Ascendis Pharma A/S (NASDAQ:ASND) insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ascendis Pharma A/S Trading Down 0.4%

NASDAQ ASND opened at $237.65 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The firm has a market cap of $14.82 billion, a PE ratio of 27.41 and a beta of 0.41. The company has a 50 day moving average price of $232.03 and a 200 day moving average price of $219.74. Ascendis Pharma A/S has a 52 week low of $150.89 and a 52 week high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post 9.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wells Fargo & Company cut their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research note on Friday. Oppenheimer increased their price objective on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Wolfe Research reiterated an “outperform” rating and issued a $260.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Morgan Stanley reiterated an “overweight” rating and issued a $256.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, February 12th. Finally, Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus price target of $291.50.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC purchased a new stake in Ascendis Pharma A/S during the third quarter worth $26,000. Arax Advisory Partners boosted its holdings in Ascendis Pharma A/S by 212.2% during the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after buying an additional 104 shares in the last quarter. Leonteq Securities AG purchased a new stake in Ascendis Pharma A/S during the fourth quarter worth $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Ascendis Pharma A/S during the fourth quarter worth $42,000. Finally, Jones Financial Companies Lllp lifted its holdings in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.